View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Nanobiotix: 1 director

A director at Nanobiotix bought 10,000 shares at 2.900EUR and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...

Emmanuel Matot
  • Emmanuel Matot
 PRESS RELEASE

RUBIS: Request to add resolutions to the agenda of the general meeting...

RUBIS: Request to add resolutions to the agenda of the general meeting on 12 june 2025, by Compagnie Nationale de Navigation    Paris, 16 May 2025, 7:45am Rubis announces that on 15 May 2025, it received a request from Compagnie Nationale de Navigation to add two draft resolutions to the agenda. These resolutions pertain to the appointment of Mr. Patrick Molis and Mrs. Anne Lauvergeon as members of the Supervisory Board for a term of three years. The Management Board welcomes the candidacies of Mr. Patrick Molis and Mrs. Anne Lauvergeon, initiated by Compagnie Nationale de Navigation, a...

 PRESS RELEASE

RUBIS: Demande d’inscription à l’ordre du jour de l’assemblée générale...

RUBIS: Demande d’inscription à l’ordre du jour de l’assemblée générale du 12 juin 2025 de résolutions complémentaires par Compagnie Nationale de Navigation    Paris, le 16 mai 2025, 07h45 Rubis annonce avoir reçu le 15 mai 2025, de la part de la Compagnie Nationale de Navigation, une demande d’inscription à l’ordre du jour de deux projets de résolutions, relatifs à la nomination de Monsieur Patrick Molis et de Madame Anne Lauvergeon en qualité de membres du Conseil de Surveillance pour une durée de trois ans. La Gérance accueille favorablement les candidatures de Monsieur Patrick Molis...

 PRESS RELEASE

RUBIS: Rubis announces the departure of Nils Christian Bergene

RUBIS: Rubis announces the departure of Nils Christian Bergene Paris, 15 May 2025, 11:15pm Nils Christian Bergene has announced today his decision to step down from his roles as Chairman and member of the Supervisory Board of Rubis. Acknowledging his resignation, the members of the Supervisory Board have met and have decided to appoint Marc-Olivier Laurent as new Chairman effective immediately. All members of the Supervisory Board of Rubis, along with the Management Board, wish to thank Nils Christian Bergene for his active contribution to the Board's work and for his leadership as Chairm...

 PRESS RELEASE

RUBIS: Rubis annonce le départ de Nils Christian Bergene

RUBIS: Rubis annonce le départ de Nils Christian Bergene Paris, le 15 mai 2025, 23h15 Nils Christian Bergene a fait part ce jour de sa décision de quitter ses fonctions de Président et de membre du Conseil de Surveillance de Rubis. Prenant acte de sa démission, les membres du Conseil de Surveillance se sont réunis et ont désigné Marc-Olivier Laurent en qualité de nouveau Président avec effet immédiat. L’ensemble des membres du Conseil de Surveillance de Rubis, auxquels s’associe le Collège de la Gérance, adresse ses sincères remerciements à Nils Christian Bergene pour sa contribution acti...

 PRESS RELEASE

Combined General Meeting of June 11, 2025

Combined General Meeting of June 11, 2025 Châtillon, France, May 15, 2025 Combined General Meeting of June 11, 2025 Procedures for Obtaining Information and Preparatory Documents for the Combined General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the “Company”), will hold its Combined General Meeting (the “General Meeting”) on June 11, 2025, at 02:00 p.m. CEST (08:00 a.m EST) at the Company’s headquarters located at IRO Building, 107 Avenue de la République, 92320 Châtillon, France. The prelimina...

 PRESS RELEASE

Assemblée Générale Mixte du 11 juin 2025

Assemblée Générale Mixte du 11 juin 2025 Châtillon, France, le 15 mai 2025 Assemblée Générale Mixte du 11 juin 2025 Modalités de mise à disposition des informations et documents préparatoires à l’Assemblée Générale Mixte DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market : DBVT), (la « Société »), société biopharmaceutique en phase clinique, tiendra son Assemblée Générale Mixte (l’«Assemblée Générale »)  le mercredi 11 juin à 14h00 (heure de Paris), au siège social de la Société, IRO Building, 107 Avenue de la République, 92320 Châtillon. L’avis de réunion com...

 PRESS RELEASE

INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’...

INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 14 mai 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Paris / NasdaqEuronext Compartiment : B Code ISIN : FR0011341205Nasdaq : NBTXBloomberg : NANO:FPReuters : NANO.PASite web : DateNombre total d’actions composant le capital socialNombre total de droits de voteTotal théorique1Total exerçable230 avril 202547 426 85149 535 88349 513 765 À prop...

 PRESS RELEASE

Voting Rights and Shares Capital of the Company

Voting Rights and Shares Capital of the Company In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, May 14, 2025 (GLOBE NEWSWIRE) -- Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: DateNumber of Shares OutstandingTotal number of voting rightsTotal voting rights, theoretical1Total voting rights,exercisable2April 30, 202547,426,85149,535,88349,513,765 About NANOBI...

 PRESS RELEASE

Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect...

Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ PARIS and CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conference: H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ Date: Tuesday, May 20, 2025Time: 5:00 pm...

 PRESS RELEASE

Nanobiotix participera à la 3ème conférence investisseurs annuelle H.C...

Nanobiotix participera à la 3ème conférence investisseurs annuelle H.C. Wainwright BioConnect au NASDAQ PARIS and CAMBRIDGE, Mass., 12 mai 2025 (GLOBE NEWSWIRE) -- (Euronext : NANO –– NASDAQ : NBTX – la « Société »), société française de biotechnologie en phase de développement clinique avancé, pionnière des approches fondées sur les nanoparticules pour élargir les possibilités de traitement des patients atteints de cancer ou d’autres maladies, annonce aujourd’hui que Nanobiotix participera à une discussion (« fireside chat ») à la conférence suivante : 3ème conférence investisseurs ann...

Oscar Haffen Lamm
  • Oscar Haffen Lamm

Medincell: Uzedy TRx shows strong demand, mdc-TJK NDA filing expected ...

Yesterday Teva presented its Q1'25 results, with Uzedy sales for the quarter coming in at USD39m (+160% YoY). While beating Teva's css (USD32.5m, +20%), sales appeared relatively flattish compared Q4 (USD43m), which could be attributed to calendar effects and stock adjustments. We remain optimistic

Christophe-Raphaël Ganet
  • Christophe-Raphaël Ganet
Christophe-Raphaël Ganet
  • Christophe-Raphaël Ganet
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch